Skip to content

Clinical trials

Lung Neoplasms trials in Spain with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Not applicable Country / region: Spain Clear all

19 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20111
20121
20131
20141
20162
20192
20201
20211
20223
20231
20242
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed9
Unknown status5
Recruiting3
Not yet recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz2
Parc de Salut Mar2
Biosistemak Institute for Health Systems Research1
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal1
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1
Galvanize Therapeutics, Inc.1
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)1
Hoffmann-La Roche1
Hospital Clinic of Barcelona1
Hospital Universitari Vall d'Hebron Research Institute1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms19
Carcinoma, Non-Small-Cell Lung2
Breast Neoplasms1
Disease1
Dyspnea1
Emphysema1
Fatigue1
Gastrointestinal Neoplasms1
Neoplasms1
Postoperative Complications1

Trials

Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.